We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Omnicell (OMCL) Beats on Earnings in Q2, Tapers '19 EPS View
Read MoreHide Full Article
Omnicell, Inc.’s (OMCL - Free Report) second-quarter 2019 adjusted earnings per share (EPS) of 67 cents outpaced the Zacks Consensus Estimate by 4.7%.
Also, adjusted EPS surged 45.6% from the year-ago figure and surpassed the company’s guided range of 61-66 cents as well.
Revenues in Detail
Adjusted revenues in the second quarter increased 15.2% year over year to $217.4 million. The top line also trumped the Zacks Consensus Estimate of $213 million.
Quarterly Details
On a segmental basis, Product revenues improved 17.7% year over year to $158.4 million in the reported quarter.
Moreover, Service and other revenues climbed 9.2% year over year to $59 million.
Operational Update
In the quarter under review, Omnicell's adjusted gross profit rose 17.2% to $104 million. Adjusted gross margin expanded 80 basis points (bps) to 47.9%.
Adjusted operating profit totaled $18.8 million, reflecting a 155.8% jump from the prior-year quarter. Adjusted operating margin in the second quarter grew 474 bps to 13%.
SG&A expenses inched up 3.8% year over year to $68.4 million. Moreover, research and development expenses escalated 8.6% year over year to $16.8 million. Also, adjusted operating expenses were $85.2 million in the second quarter, up 4.7% year over year.
Financial Update
Omnicell exited the second quarter with cash and cash equivalents of $87.5 million compared with $77.2 million at the end of the first quarter.
Guidance
For the third quarter of 2019, Omnicell expects adjusted revenues between $227 million and $233 million. The Zacks Consensus Estimate for the metric stands at $231.9 million, within the guided range.
On an adjusted basis, product revenues are expected between $168 million and $173 million while service revenues are projected within $59-$60 million.
Third-quarter adjusted EPS is envisioned in the band of 67-72 cents. The Zacks Consensus Estimate for the same is pegged at 71 cents, close to the upper end of the predicted range.
For 2019, adjusted revenues are now anticipated within $886-$900 million, narrowed from the earlier band of $880-$900 million. The Zacks Consensus Estimate for the same is pinned on $891.9 million, within the guided range.
Product revenues for the full year are estimated within $653-$663 million while service revenues are expected between $233 million and $237 million.
Adjusted EPS is forecast between $2.65 and $2.82 for 2019 (earlier range was $2.62-$2.82). The Zacks Consensus Estimate for the metric stands at $2.77, within the guided range.
Our Take
Omnicell delivered impressive second-quarter 2019 results. The company continued to see solid segmental contributions. Its solid year-over-year EPS growth is a major positive. Moreover, Omnicell inked various deals for both the XR2 and the IVX Workflow products. It issued an upbeat guidance for the third quarter as well as 2019.
Currently, the company is working on product innovation through R&D. Moving ahead, Omnicell is expected to gain traction from product launches, strategic partnerships and digital transformation. Expansion of gross and operating margins in the reported quarter is encouraging as well.
However, a tough competitive landscape acts as a dampener.
Zacks Rank
Omnicell currently carries a Zacks Rank #3 (Hold). A few better-ranked stocks in the broader medical space are Hologic Inc. (HOLX - Free Report) , DENTSPLY SIRONA Inc. (XRAY - Free Report) and Teleflex Inc. (TFX - Free Report) .
Hologic is scheduled to release second-quarter 2019 results on Jul 31. The Zacks Consensus Estimate for the quarter’s adjusted EPS is pegged at 61 cents and for revenues, stands at $834.6 million. The stock carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
DENTSPLY SIRONA is scheduled to release second-quarter 2019 results on Aug 2. The Zacks Consensus Estimate for its adjusted EPS is pinned on 62 cents and for revenues, stands at $1.03 billion. The stock sports a Zacks Rank #1.
Teleflex is expected to release second-quarter 2019 results on Aug 1. The Zacks Consensus Estimate for its adjusted EPS is $2.59 and its top line, $636.7 million. The stock has a Zacks Rank of 2.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 7 stocks to watch. The report is only available for a limited time.
Image: Bigstock
Omnicell (OMCL) Beats on Earnings in Q2, Tapers '19 EPS View
Omnicell, Inc.’s (OMCL - Free Report) second-quarter 2019 adjusted earnings per share (EPS) of 67 cents outpaced the Zacks Consensus Estimate by 4.7%.
Also, adjusted EPS surged 45.6% from the year-ago figure and surpassed the company’s guided range of 61-66 cents as well.
Revenues in Detail
Adjusted revenues in the second quarter increased 15.2% year over year to $217.4 million. The top line also trumped the Zacks Consensus Estimate of $213 million.
Quarterly Details
On a segmental basis, Product revenues improved 17.7% year over year to $158.4 million in the reported quarter.
Moreover, Service and other revenues climbed 9.2% year over year to $59 million.
Operational Update
In the quarter under review, Omnicell's adjusted gross profit rose 17.2% to $104 million. Adjusted gross margin expanded 80 basis points (bps) to 47.9%.
Omnicell, Inc. Price, Consensus and EPS Surprise
Omnicell, Inc. price-consensus-eps-surprise-chart | Omnicell, Inc. Quote
Adjusted operating profit totaled $18.8 million, reflecting a 155.8% jump from the prior-year quarter. Adjusted operating margin in the second quarter grew 474 bps to 13%.
SG&A expenses inched up 3.8% year over year to $68.4 million. Moreover, research and development expenses escalated 8.6% year over year to $16.8 million. Also, adjusted operating expenses were $85.2 million in the second quarter, up 4.7% year over year.
Financial Update
Omnicell exited the second quarter with cash and cash equivalents of $87.5 million compared with $77.2 million at the end of the first quarter.
Guidance
For the third quarter of 2019, Omnicell expects adjusted revenues between $227 million and $233 million. The Zacks Consensus Estimate for the metric stands at $231.9 million, within the guided range.
On an adjusted basis, product revenues are expected between $168 million and $173 million while service revenues are projected within $59-$60 million.
Third-quarter adjusted EPS is envisioned in the band of 67-72 cents. The Zacks Consensus Estimate for the same is pegged at 71 cents, close to the upper end of the predicted range.
For 2019, adjusted revenues are now anticipated within $886-$900 million, narrowed from the earlier band of $880-$900 million. The Zacks Consensus Estimate for the same is pinned on $891.9 million, within the guided range.
Product revenues for the full year are estimated within $653-$663 million while service revenues are expected between $233 million and $237 million.
Adjusted EPS is forecast between $2.65 and $2.82 for 2019 (earlier range was $2.62-$2.82). The Zacks Consensus Estimate for the metric stands at $2.77, within the guided range.
Our Take
Omnicell delivered impressive second-quarter 2019 results. The company continued to see solid segmental contributions. Its solid year-over-year EPS growth is a major positive. Moreover, Omnicell inked various deals for both the XR2 and the IVX Workflow products. It issued an upbeat guidance for the third quarter as well as 2019.
Currently, the company is working on product innovation through R&D. Moving ahead, Omnicell is expected to gain traction from product launches, strategic partnerships and digital transformation. Expansion of gross and operating margins in the reported quarter is encouraging as well.
However, a tough competitive landscape acts as a dampener.
Zacks Rank
Omnicell currently carries a Zacks Rank #3 (Hold). A few better-ranked stocks in the broader medical space are Hologic Inc. (HOLX - Free Report) , DENTSPLY SIRONA Inc. (XRAY - Free Report) and Teleflex Inc. (TFX - Free Report) .
Hologic is scheduled to release second-quarter 2019 results on Jul 31. The Zacks Consensus Estimate for the quarter’s adjusted EPS is pegged at 61 cents and for revenues, stands at $834.6 million. The stock carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
DENTSPLY SIRONA is scheduled to release second-quarter 2019 results on Aug 2. The Zacks Consensus Estimate for its adjusted EPS is pinned on 62 cents and for revenues, stands at $1.03 billion. The stock sports a Zacks Rank #1.
Teleflex is expected to release second-quarter 2019 results on Aug 1. The Zacks Consensus Estimate for its adjusted EPS is $2.59 and its top line, $636.7 million. The stock has a Zacks Rank of 2.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 7 stocks to watch. The report is only available for a limited time.
See 7 breakthrough stocks now>>